IRIS
CRETELLA, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.257
EU - Europa 919
AS - Asia 547
AF - Africa 10
SA - Sud America 3
OC - Oceania 1
Totale 2.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.253
CN - Cina 318
IT - Italia 225
IE - Irlanda 218
SE - Svezia 193
SG - Singapore 143
FI - Finlandia 102
DE - Germania 52
TR - Turchia 32
AT - Austria 27
BE - Belgio 25
IN - India 25
FR - Francia 21
GB - Regno Unito 17
CZ - Repubblica Ceca 12
CI - Costa d'Avorio 10
HK - Hong Kong 10
UA - Ucraina 10
VN - Vietnam 8
CA - Canada 4
PL - Polonia 4
IR - Iran 3
JP - Giappone 3
NL - Olanda 3
RU - Federazione Russa 3
CH - Svizzera 2
HU - Ungheria 2
KR - Corea 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
HR - Croazia 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PE - Perù 1
RO - Romania 1
Totale 2.737
Salva come PNG Salva come JPEG
Città #
Chandler 246
Ann Arbor 240
Dublin 218
Singapore 113
Parma 101
Dearborn 85
Ashburn 60
Boardman 55
Shanghai 51
Beijing 44
Nanjing 40
Princeton 35
New York 34
Izmir 32
Bremen 27
Vienna 27
Wilmington 21
Shenyang 20
Nanchang 18
Helsinki 17
Jinan 17
Hebei 16
Redmond 16
Kunming 15
Woodbridge 15
Brussels 14
Des Moines 14
Los Angeles 14
San Mateo 14
Pune 12
Wayne 12
Hefei 11
Abidjan 10
Hong Kong 10
Jiaxing 10
Norwalk 10
Dong Ket 8
Modena 8
Rio Saliceto 8
Binche 7
Brno 7
Fremont 7
Jacksonville 7
Munich 7
Tianjin 7
Fuzhou 6
Guangzhou 6
Seattle 6
Leawood 5
Redwood City 5
Changsha 4
Mons 4
Santa Clara 4
Ardabil 3
Fairfield 3
Falls Church 3
Genoa 3
Grafing 3
Houston 3
Lanzhou 3
Manchester 3
Marseille 3
Monmouth Junction 3
Prata Di Pordenone 3
Rome 3
Rubiera 3
Taiyuan 3
Augusta 2
Carpenedolo 2
Casalgrande 2
Chengdu 2
Dallas 2
Edinburgh 2
Frankfurt am Main 2
Haikou 2
Huizen 2
Katowice 2
Kraków 2
London 2
Montegaldella 2
Mumbai 2
Pesaro 2
Philadelphia 2
Phoenix 2
Reggio Nell'emilia 2
Rockville 2
Rottofreno 2
Scottsdale 2
Sorbolo 2
Toronto 2
Trieste 2
Vallefoglia 2
Zhengzhou 2
Zurich 2
Amman 1
Auckland 1
Bacoli 1
Bangalore 1
Baotou 1
Brescia 1
Totale 1.902
Salva come PNG Salva come JPEG
Nome #
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 126
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 125
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 117
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 112
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 107
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 105
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 104
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 100
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 98
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 94
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 94
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 92
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 90
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 88
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 87
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 86
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 79
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 78
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 76
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 74
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 73
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 68
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 65
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 65
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 64
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 64
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 62
CDK4/6 inhibitors in HER2-positive breast cancer 57
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 55
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 54
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 54
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 52
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 50
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 45
Targeting FGFR1 pathway in squamous cell lung cancer 44
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 34
Totale 2.838
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020340 0 0 0 0 23 75 73 23 52 46 31 17
2020/2021273 7 12 7 19 25 16 19 31 36 22 43 36
2021/2022232 28 12 21 14 4 3 30 10 10 12 11 77
2022/2023877 80 107 61 69 82 102 4 57 261 3 40 11
2023/2024337 21 30 2 15 31 78 35 28 13 23 22 39
2024/2025225 19 39 51 69 47 0 0 0 0 0 0 0
Totale 2.838